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Infections are a common complication arising after kidney transplantation with a high rate of morbidity and mortality. 
Since the beginning of the COVID-19 pandemic, it has been reported that the kidney transplant recipient population have 
the worst outcome and highest rate of mortality. The pandemic greatly infl uences the management of chronic kidney 
failure and transplantation programs. This review describes clinical presentation and risk factors linked to COVID-19, the 
management and outcomes, COVID-19 vaccination in kidney transplant recipients, and the impact of COVID-19 on renal 
transplantation programs.
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INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) was found to cause COVID-19 and has 
spread in waves throughout the world since the end 
of 2019. Until May 28, 2021, more than 168 million 
COVID-19 confi rmed cases, 3.5 million deaths, and 
more than 1.5 billion doses of vaccine administered 
worldwide have been recorded (1). 
Kidney transplant recipients (KTR) are considered to 
be at a high risk of COVID-19, with the worst out-
come due to immunosuppression and clinical presen-
tation that might diff er from what is seen in the gen-
eral population. Th is review mainly focuses on clinical 
presentation and risk factors of COVID-19 in KTR, 
immunosuppression management and outcomes, and 
the infl uence of the COVID-19 pandemic on renal 
transplant programs. 
CLINICAL PRESENTATION AND RISK FACTORS
As in the general population, KTR with COVID-19 
infection mainly present with fever and respirato-
ry symptoms such as cough and dyspnea. In some 
kidney transplant patients, fever may be absent (2). 
More recently, multiple studies have elucidated that 
COVID-19 is a systemic disease oft en manifesting 
with gastrointestinal (GI) symptoms, liver injury, car-
diac involvement, encephalitis, atypical stroke, and 
acute kidney injury (AKI), in addition to endothelial 
cell injury and coagulopathy, the likely mediators of 
multiorgan involvement (3). Symptoms such as cough, 
shortness of breath, myalgia, headache, sore throat, 
and GI symptoms are more common in KTR than the 
typical COVID-19 presentation. Additionally, sever-
al unreported symptoms such as chest tightness and 
pain, coryza, dehydration, conjunctivitis, dizziness, 
and weight loss appeared in the SARS-CoV-2 posi-
tive KTR. Non-white ethnicity, obesity, diabetes, and 
asthma/chronic pulmonary diseases are risk factors 
independently associated with COVID-19 disease in 
patients with kidney transplants and immunosuppres-
sion modulation (4). Other risk factors are advanced 
age, male gender, not to mention immunosuppression 
itself. Th e burden of comorbidities such as diabetes 
and hypertension, which are mostly reported as signif-
icant factors infl uencing the outcome of COVID-19, 
as well as smoking and cardiovascular disease fur-
ther compromise outcomes in KTR with COVID-19 
(2,3,5).
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ENDSTAGE RENAL DISEASE AND COVID19
End-stage renal disease (ESRD) is considered when 
chronic injury to the kidney leads to decreased func-
tioning of the organ with a glomerular fi ltration rate 
(GFR) below 15 mL/min/1.73 m2 (6). At this level, 
renal replacement therapy (RRT) with either perito-
neal dialysis, hemodialysis, or kidney transplantation 
should be initiated. In a review study, Valeri reports 
an infection rate of COVID-19 between 11%-26% 
among patients with ESRD, with a mortality rate of up 
to 24%-27%, which is 6-7 times higher than the rate 
of 4% reported in the global population (7). Th us, giv-
en the immunocompromised nature of ESRD and the 
high comorbidity burden seen in patients with kidney 
failure, patients with ESRD are among the most vul-
nerable populations to COVID-19. 
Similar to the general population, the most common 
presenting symptoms in ESRD patients remain fever 
and cough (8,9). In contrast, Ferrey et al. described an 
atypical presentation with symptoms of gastroenteri-
tis in ESRD patients, which was similar to KTR (10). 
Adapa et al. report on acute kidney injury (AKI) to be 
an independent risk factor for mortality in COVID-19 
patients, with an incidence of 3%-15%. In patients 
with severe infection requiring intensive care, the 
rates of AKI increased signifi cantly from 15% to 50% 
(11). Another concern is the high incidence of AKI 
in patients infected with COVID-19 requiring hospi-
tal resources that strain intensive care units and ven-
tilator capacity and renal replacement resources (7). 
In COVID-19 patients with severe AKI and with es-
tablished ESRD, continuation of their RRT is vital for 
survival. It is recommended that healthcare personnel 
should follow what the Centre for Disease Control 
recommends for personal protective equipment and 
safety guidelines during their interactions with those 
patients to decrease the spread of infection and noso-
comial acquisition in RRT centers (11).
It has been recommended that hospitalized patients 
with COVID-19 who experience any form of AKI 
should be followed up closely aft er discharge to assess 
the ongoing kidney function (12). 
OUTCOMES OF COVID19 IN KIDNEY 
TRANSPLANT RECIPIENTS
Th e mortality rate of COVID-19 in KTR is at least four 
times higher than in the general population (2). Elias 
et al. report a high mortality rate among KTR with 
COVID-19, fl uctuating between 20% and 28% as com-
pared with 1%-5% mortality in the general population 
(4). Coronavirus pandemic is too recent and current-
ly, data on the clinical course, imaging features, and 
outcomes in KTR have not yet been fully elucidated. 
In a study on 12 patients, where ten were admitted to 
the intensive care unit, nine were intubated, eight died 
of severe COVID-19 pneumonia and acute respiratory 
distress syndrome (ARDS), and four were discharged 
aft er complete recovery, Abrishami et al. report that 
the most common pattern of lung involvement was 
bilateral involvement with a diff use pattern and pos-
terior segmental distribution. Ground glass opacity, a 
feature highly suggestive of COVID-19, was observed 
in all cases and consolidation in the majority of them 
(Figure 1). 
Fig. 1. Chest computerized tomography in a renal transplant 
recipient with SARS-CoV-2 infection. Bilateral ground glass 
opacities with a diff use pattern are present with areas of 
consolidation.
Th e authors concluded that interlobular septal thick-
ening, multilobar patterns, consolidative lesions, and 
a high score for lung involvement were more frequent 
among patients with poor outcomes and complicat-
ed cases with acute respiratory distress syndrome 
(ARDS) (13). Jawdeh reports an elevated incidence of 
AKI and a mortality rate of 13%-30%, which is higher 
than that in the general population (∼5%). Th is could 
be attributed to the increased prevalence of comorbid-
ities in addition to the immunosuppressed state lead-
ing to severe COVID-19 (3). Other studies have also 
found male gender to be associated with high mortal-
ity in COVID-19 infected KTR (3,14). Craig-Schap-
iro et al. also report that there was the need for RRT 
in hospitalized patients and that high infl ammatory 
markers such as D-dimer, procalcitonin, and C-reac-
tive protein were associated with high mortality (14). 
Th e management is mainly performed in patients pre-
senting with severe symptoms such as dyspnea and 
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requiring mechanical ventilation, with immunosup-
pression reduction and supportive therapy in most 
patients (4,15).
MANAGEMENT OF COVID19 IN KIDNEY 
TRANSPLANT RECIPIENTS 
Immunocompromised patients, including those on 
immunosuppression following solid organ trans-
plantation, are considered to be at a high risk of se-
vere COVID-19. At this time, supportive care is par-
amount to combat this virus in solid organ transplant 
recipients. Little data are currently available regarding 
optimal medical management of KTR testing positive 
for SARS‐CoV‐2, including strategies for reducing 
or modifying immunosuppression. Elias et al. report 
that managing immunosuppression in patients with 
COVID-19 disease is arduous (4). Corticosteroids are 
a cornerstone of many immunosuppressive regimens; 
however, their use in SARS‐CoV‐2 remains controver-
sial (4,16). Increased mortality recorded in transplant 
recipients with COVID-19 corroborates the role of 
diminished T- and B-cell immunity as a predisposing 
factor for severe infection. It would be reasonable to 
hold the antimetabolite in those with moderate dis-
ease and continue low-dose calcineurin inhibitor with 
or without glucocorticoids. In patients with severe dis-
ease and in critically ill patients, it may be justifi able 
to hold all maintenance immunosuppression except 
for steroids (3,17). Banerjee et al. suggest that antipro-
liferative agents (mycophenolate mofetil and azathio-
prine) be stopped at the time of admission to the hos-
pital, the dose of prednisolone be either unchanged or 
increased, and tacrolimus dose be reduced. In severe 
infections (requiring intubation and ventilation), an 
argument can be made for stopping calcineurin in-
hibitors completely while maintaining corticosteroid 
therapy (5). Th is is in line with our approach that re-
sulted in 7% mortality rate. An individual approach is 
mandatory with the decision based on disease severity, 
patient characteristics, and immunologic risk.
In a national survey in the United States, Boyarsky et 
al. report that antimetabolites were reported to have 
been stopped by 92.3% of respondents and calcineurin 
inhibitors were reduced by 26.9% of respondents (18). 
It has been reported that 81% of COVID-19 patients 
present with mild disease and can be managed at 
home. In contrast, severe and critical COVID-19 dis-
ease should be managed with prompt hospitalization 
while ensuring appropriate infection control and sup-
portive care, with empiric treatment for bacterial in-
fections, prevention of venous thromboembolism, and 
avoiding nebulized medications (2). Since patients 
should consider the risks and benefi ts of any treat-
ment before giving their consent, the risks associated 
with minimizing or discontinuing immunosuppres-
sants, thus potentially changing the fate of functioning 
kidney transplantation, should be clearly explained so 
that patients can make a well-informed decision (19).
INFLUENCE OF COVID19 PANDEMIC ON 
RENAL TRANSPLANT PROGRAMS
Th e COVID-19 pandemic has pushed the world to re-
think, reshape and adapt in the way everything works. 
Regarding renal transplant programs, the fear of al-
legedly increased susceptibility to infections in KTR 
due to immunosuppression has forced many centers to 
shut down their transplantation unit or change the par-
adigm and thus the routine of workfl ow. Th e reduction 
in transplantation volume during this time is partly due 
to concerns about the potential increased susceptibility 
and worsened outcomes of COVID-19 in immunosup-
pressed recipients (14). Loupy et al. report on strong 
association between rising coronavirus infections and 
marked reduction in the overall number of solid-or-
gan transplantation, even in geographic regions with 
a low infection prevalence (20). In a national survey 
conducted in the United States linked to COVID-19 
and transplantation, Boyarsky et al. report on complete 
suspension of living donor transplantations by 71.8%. 
However, most deceased donor programs in the Unit-
ed States continued to function with some restrictions 
(18), whereas in the United Kingdom, kidney trans-
plant programs had to suspend temporarily both the 
deceased and living donor transplantation (21). Th e 
underlying reasons were to release/create more inten-
sive care beds, liberate the workforce to support the 
intensive care unit, and, more importantly, prevent in-
crease in mortality due to COVID-19 in immunosup-
pressed individuals (20). Concerning transplant proce-
dures, SARS-CoV-2 infection could be missed in both 
donors and recipients who are asymptomatic, owing to 
the sensitivity issues in the RT-PCR test.
Additionally, in the immediate postoperative period 
and aft er hospital discharge, transplanted patients 
have increased susceptibility to SARS-CoV-2 infec-
tion due to induction therapy and immunosuppres-
sive treatment (22). Until today, insuffi  cient evidence 
is available to consider kidney transplantation as a safe 
procedure in COVID-19 pandemic areas. In emer-
gencies, e.g., in cases of no vascular access, unfeasible 
dialysis, or a hyperimmune state, the benefi ts might 
outweigh the risks of kidney transplant (22). Kidney 
organs are not readily available and the number of 
patients on the waiting list keeps growing. All around 
the world guidelines are being set to increase the safe-
ty peri-, during, and post-transplantation procedures 
during the current pandemic, and specifi cally to avoid 
nosocomial COVID-19 infections. 
C. A. T. Kuitcheu, N. Bašić-Jukić
COVID-19 pandemic and kidney transplantation
Acta Med Croatica, 75 (2021) 137-141
140
Th e number of kidney transplantations in Croatia has 
dramatically decreased over the last year. Faced with 
the pandemic spreading in waves, the country has 
answered the epidemiologic challenges. However, the 
number of transplantations performed has fallen to 
the levels achieved during the war. 
COVID19 VACCINATION IN KIDNEY 
TRANSPLANT RECIPIENTS
Th e vaccine-preventable disease can cause adverse pa-
tient and allograft  outcomes in KTR and live-attenu-
ated vaccinations are contraindicated in KTRs due to 
the risk of infection (23). With the current COVID-19 
pandemic, Ikizler et al. provide data suggesting that 
complete vaccination protocols should be implement-
ed in patients receiving maintenance hemodialysis 
and in KTR (24). In the absence of confi rmed asso-
ciation between natural SARS-CoV-2 infection and 
acute allograft  rejection in KTR (25,26), it is unlikely 
that vaccine antigens would precipitate clinically sig-
nifi cant immune responses to renal allograft s. Th us, 
recommendations are to administer SARS-CoV-2 
vaccine pre-transplantation when possible or at least 
at 3 months post-transplantation. Nevertheless, future 
evaluations of SARS-CoV-2 vaccine platforms in KTR 
must confi rm their safety and immunogenicity (25). 
Considering only humoral response, Cucchiari et al. 
report that S-specifi c antibodies were developed only 
by 29.9% of patients in their study population (27). 
Grupper et al. report on a 37.5% antibody response 
rate aft er the second dose of the BNT162b2 (Pfi zer) 
vaccine (26). Boyarsky et al. have recently reported 
a higher seroconversion of 54% in patients receiving 
an mRNA-vaccine, either mRNA-1273 (Moderna) or 
BNT162b2 (Pfi zer) (28). Considering the percentage 
of patients who had positive S-ELISpot aft er the sec-
ond dose, the percentage of patients who developed 
either humoral or cellular response increased to 65% 
and half of the antibody-negative patients had devel-
oped positive ELISpot. Th is fi nding highlights that pa-
tients may be protected against SARS-CoV-2 despite 
the absence of S antibodies (27).
We were the fi rst to report COVID-19 in patients who 
had completed the vaccination program (29-31), indi-
cating a high risk of nonresponding to the vaccination. 
CONCLUSION
Kidney transplant recipients remain a population at 
risk of COVID-19 infection due to their immuno-
suppression status, high morbidity and mortality. All 
over the world, the pandemic of COVID-19 has forced 
transplant programs to either shut down or to readapt. 
Vulnerable KTR patients who are not yet vaccinated 
or are non-responsive to mRNA vaccines should be 
closely followed up and sanitary protection measures 
strictly respected. 
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Infekcije su česta komplikacija nakon transplantacije bubrega. Povezane su s visokom stopom pobola i smrtnosti. Od 
samog početka pandemije COVID-19 uočeno je da bolesnici s transplantiranim bubregom imaju lošije ishode i višu stopu 
smrtnosti u usporedbi s općom populacijom. Pandemija COVID-19 je značajno utjecala na zbrinjavanje bolesnika sa za-
vršnim stadijem kronične bubrežne bolesti i na transplantacijske programe. Prikazujemo klinički nastup, čimbenike rizika, 
liječenje i ishode COVID-19 u populaciji bolesnika s transplantiranim bubregom, kao i utjecaj pandemije na transplantacij-
ske programe.
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